Neogen Shares Rise 8% in 1 Day Since Earnings Call

Key highlights

• Core revenue reached $222.8 million representing an 8.1 percent organic increase
• Food Safety segment revenue grew 8.1 percent driven largely by Petrifilm product demand
• Animal Safety segment revenue increased 8 percent behind solid commercial execution
• Management raised fiscal year 2027 revenue guidance to a range of $885 million to $890 million
• The company entered a definitive agreement to sell its global Genomics business for $160 million
• Order timing and prior year inventory comparisons provided a 300 basis point benefit to growth

Financial Performance

Neogen reported total revenue of $222.8 million for the period, marking an 8.1 percent increase in core revenue. This growth was distributed evenly across the company's primary reporting lines, with Food Safety and Animal Safety both seeing approximately 8 percent gains. However, management noted that the growth figure was bolstered by approximately 300 basis points due to favorable order timing and comparisons against lower distributor inventory levels in the prior year. The company continues to focus on debt reduction and operational efficiency as it manages the integration of its larger manufacturing footprint.

Down 1.9% since our story on 6 Oct: $11.96 when we broke it → $11.73 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$11.95
15 Sep	$12.25
16 Sep	$12.55
17 Sep	$12.83
18 Sep	$13.00
21 Sep	$13.61
22 Sep	$13.98
23 Sep	$13.57
24 Sep	$13.66
25 Sep	$13.76
28 Sep	$13.72
29 Sep	$12.73
30 Sep	$12.80
1 Oct	$12.24
2 Oct	$12.15
5 Oct	$13.01
6 Oct	$11.96
7 Oct	$11.68
8 Oct	$11.71
9 Oct	$11.85
12 Oct	$12.00
13 Oct	$11.73

Management Outlook

Following the quarterly results, Neogen updated its guidance for fiscal year 2027. The company now expects total revenue to fall between $885 million and $890 million, up from the previous range of $880 million to $885 million. Adjusted EBITDA expectations were also moved higher, now projected at $181 million to $183 million. A significant component of the forward-looking strategy involves the divestiture of the global Genomics business to Zoetis Inc. for $160 million, a transaction expected to close by the end of the calendar year 2026 pending regulatory approvals.

Business Overview

Neogen Corporation operates within the healthcare sector, specifically focusing on the medical devices and diagnostics industry. The company develops and markets products dedicated to food and animal safety. Its Food Safety segment consists primarily of diagnostic test kits and related products used by food producers to detect dangerous substances, while the Animal Safety segment focuses on biosecurity products, veterinary instruments, and pharmaceuticals. The company is currently in the midst of a multi-quarter manufacturing transition involving its Petrifilm product line.

Sector Dynamics

The industry is currently navigating a period of stabilization in distributor inventory levels after previous fluctuations. Neogen's performance reflects a broader trend of steady demand for food safety diagnostics, though operational results are being impacted by manufacturing transfers. The company is preparing to start the Petrifilm manufacturing transfer next month, a move intended to de-risk long-term production. Meanwhile, the strategic pivot away from the Genomics business highlights a sector-wide trend of companies streamlining portfolios to focus on core high-growth diagnostic segments.

What to Watch

• The scheduled Investor Day in New York City on October 7 2026 where management may provide further strategic details
• The progress of the Petrifilm manufacturing transfer beginning next month
• Regulatory clearance and closing of the 160 million dollar Genomics business sale to Zoetis
• The impact of the manufacturing transition on operating margins over the next several quarters

Manufacturing Transition Strategy

“Petrifilm manufacturing transfer begins next month; multi-quarter transition expected to de-risk operations.”

Management commentary

“Neogen delivered 8.1% core revenue growth, driven by commercial execution and Petrifilm strength, while progressing on its multi-quarter manufacturing transition and debt reduction.”

Neogen Corporation · financial snapshot

Share price	$11.96
Market cap	$2.6B
Revenue (annual)	$870M
1-month price change	+2.75%
Sector	HealthcareMedical Devices

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.